The coronavirus pandemic has had a severe impact on healthcare services but one area where that has been felt particularly deeply is with lung cancer screening. With sessions cancelled, treatment delays and social-distancing and safety requirements, many patients have been affected. However, as services begin to pick up again and lung cancer screening returns, three experts closely associated…
The evolving area of immunotherapies in lung cancer and the role of iRecist treatment assessment protocols were investigated during a virtual session organised by the British Institute of Radiology (BIR). Consultant radiologist Dr Charlie Sayer, specialist in lung cancer imaging at the Brighton and Sussex University Hospitals Trust, South of England, focused on immunotherapies, the limitations of…
The role of Low Dose Computed tomography (LDCT) screening for lung cancer has been under debate for decades. The screening uses a low dose of an imaging procedure that uses special x-ray equipment to create detailed pictures, or scans, of areas inside the body. The results of two major clinical trials have provided evidence on lung cancer-related mortality reduction as a result of LDCT.
Smoking is strongly linked to lower use of cancer screening services by women, and more advanced disease once cancer is diagnosed, new research reveals. Tobacco use is falling in many parts of the world, but it’s falling less rapidly among women than it is among men. And lung cancer remains the leading cause of cancer death among women, say the researchers. The evidence also suggests that women…
Tiny finger-like projections called filopodia drive invasive behavior in a rare subset of lung cancer cells, researchers at Winship Cancer Institute of Emory University have found. Adam Marcus’ lab has developed innovative techniques for separating “leaders” and “followers,” subpopulations of tumor cells that cooperate during the process of metastasis. The lab’s new analysis of what…
Better outcomes, more favourable prognoses – oncologists and their lung cancer patients didn’t dare to dream about it. Finally, there might be hope. The so-called checkpoint inhibitors (immunotherapy drug) have been used successfully, albeit not for every patient. They are a double-edged sword, with risks as well as opportunities, as explained by Professor Cornelia Schäfer-Prokop.
Computer scientists working with pathologists have trained an artificial intelligence (AI) tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment. The AI tool was able to differentiate between immune cells and cancer cells, enabling researchers to build a detailed picture of how lung cancers evolve in response to the immune system in…
A receptor in the cell layer that lines the blood vessels from the inside stimulates both the formation of new blood vessels in tumors and metastasis.
The Heidelberg Thorax Clinic is trialling a newly structured, longitudinal communication concept to meet proactively the complex needs of stage IV lung cancer patients and their relatives. The concept is aimed at enhancing prognostic understanding and building the basis for proactive care planning, early integration of palliative care and shared decision-making, ultimately improving overall care.
People who are at high risk of developing lung cancer, such as heavy smokers, are routinely screened with computed tomography (CT), which can detect tumors in the lungs. However, this test has an extremely high rate of false positives, as it also picks up benign nodules in the lungs. Researchers at the Massachussetts Institute of Technology (MIT) have now developed a new approach to early…
The publication of the results of the Dutch-Belgian lung cancer screening trial (NELSON) supports recent calls to introduce lung cancer screening programmes throughout Europe. In light of the scientific evidence, lung cancer screening should be firmly embedded in any initiative launched by the European Commission and the Member States in the fight against cancer. As the leading cause of death…
The need to consider a formal recommendation on early screening for lung cancer was acknowledged by the Cross Party Group for Cancer, held at the Scottish Parliament in Edinburgh in January. Attended by over 40 people representing patients, the medical community, and the pharmaceutical industry as well as political advisers and Members of the Scottish Parliament, the Group agreed to write to the…
Scientists from the Case Western Reserve University digital imaging lab use Artificial Intelligence (AI) to predict which lung-cancer patients will benefit from expensive immunotherapy. This is done by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy…
Under the auspices of the Member of the European Parliament (MEP) Claudia Gamon, the European Society of Radiology (ESR), the European Respiratory Society (ERS) and Lung Cancer Europe (LuCE) have joined forces to organise an event at the European Parliament and publish a factsheet that aims to raise awareness of lung cancer and the need for increased visibility of the disease in European Union…
For lung cancer patients, life expectancy has hardly improved since 1970. A ten-year survival is 5%, making this the leading cause of death among all cancers. One reason is that, in most cases, the disease is diagnosed far too late. Professor Mathias Prokop is among leading advocates of low-dose CT screening for lung cancer for high risk patients.
Oncimmune Holdings plc, a leading global immunodiagnostics group, announces it has entered into an exclusive partnership agreement which it believes will unlock the full potential of EarlyCDT Lung in the United States, bringing this lung cancer test to more patients as a result. This agreement with Biodesix, Inc., a leading lung cancer diagnostic solutions company, encompasses both the…
Is computed tomography suitable for detecting lung cancer at a very early stage and thus still well treatable? Scientists at the German Cancer Research Center have investigated this with the LUSI study started in 2007. The results of the study, which is funded by the Deutsche Forschungsgemeinschaft and the Dietmar Hopp Foundation, are now available.
Scientists from King's and Cambridge have developed a catalogue of DNA mutation ‘fingerprints’ that could help doctors pinpoint the environmental culprit responsible for a patient’s tumour – including showing some of the fingerprints left in lung tumours by specific chemicals found in tobacco smoke. Our DNA, the human genome, comprises of a string of molecules known as nucleotides. These…
Test more accurately identifies four mutations for which FDA-approved drugs exist and offers faster turn-around time between initial testing and commencement of therapy.
A new radiomics study could help unlock one of the more challenging issues facing thoracic radiologists. Distinguishing non-small cell lung cancer from benign nodules is a major challenge due to their similar appearance on CT images. Now, however, researchers from Case Western Reserve University in Cleveland, Ohio, have used radiomic features extracted from CT images to differentiate between…
Before lung cancer develops, precancerous lesions are found in the airway, but only half of these will actually become lung cancer, while others will disappear or remain benign without becoming harmful. Under the microscope, the lesions look the same, making it difficult to know which lesions to treat. In this study, published in Nature Medicine, researchers have for the first time, discovered…
Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented by Loyola Medicine researcher Kathy Albain, MD, at the International Association for the Study of Lung Cancer's 19th World Conference on Lung Cancer in Toronto.
Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications. They found lung squamous cell carcinoma (LUSC) cells contained high amounts of a protein called BCL11A. The study showed that manipulating the gene responsible for the protein stopped the development of LUSC in…
A test that analyzes free-floating DNA in the blood may be able to detect early-stage lung cancer, a preliminary report from the ongoing Circulating Cell-Free Genome Atlas (CCGA) study suggests. Lead study author Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute: “There is an unmet need globally for early-detection tests for lung cancer that can be easily implemented by health-care…
With the help of a new radioactive tracer, doctors can predict with more than 80 percent accuracy how well a widely-used lung cancer drug will combat tumors, according to researchers at Stanford. The researchers developed a PET scan-compatible imaging agent engineered to seek out a specific mutation found in nonsmall cell lung cancer (which accounts for about 80 percent of lung cancers), bind to…